Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Robinson

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
European Journal of Pharmacology|May 13, 2022
Effects of the serotonin 5-HT<sub>1B</sub> receptor agonist CP 94253 on the locomotor activity and body temperature of preweanling and adult male and female ratsSanders A McDougall, Matthew J Roe, Jasmine A M Robinson, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2011
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's diseaseM A Kamm, S B Hanauer, R Panaccione, et al.
Journal of Neural Engineering|August 11, 2011
Spread of cochlear excitation during stimulation with pulsed infrared radiation: inferior colliculus measurementsC-P Richter, S M Rajguru, A I Matic, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Alimentary Pharmacology & Therapeutics|September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitisB Jharap, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|March 20, 2010
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's diseaseR Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 28, 2019
OPTN/SRTR 2017 Annual Data Report: HeartM Colvin, J M Smith, N Hadley, et al.
Alimentary Pharmacology & Therapeutics|November 24, 2012
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2W J Sandborn, J-F Colombel, G D'Haens, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
European Journal of Pharmacology|May 13, 2022
Effects of the serotonin 5-HT<sub>1B</sub> receptor agonist CP 94253 on the locomotor activity and body temperature of preweanling and adult male and female ratsSanders A McDougall, Matthew J Roe, Jasmine A M Robinson, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2011
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's diseaseM A Kamm, S B Hanauer, R Panaccione, et al.
Journal of Neural Engineering|August 11, 2011
Spread of cochlear excitation during stimulation with pulsed infrared radiation: inferior colliculus measurementsC-P Richter, S M Rajguru, A I Matic, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Alimentary Pharmacology & Therapeutics|September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitisB Jharap, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|March 20, 2010
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's diseaseR Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 28, 2019
OPTN/SRTR 2017 Annual Data Report: HeartM Colvin, J M Smith, N Hadley, et al.
Alimentary Pharmacology & Therapeutics|November 24, 2012
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2W J Sandborn, J-F Colombel, G D'Haens, et al.
Pageof 13